1. P449 Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial. (25th January 2019) Authors: Ellis, J; Marks, D; Barrett, C; Hopkins, T; Richards, A; Fuhr, R; Albayaty, M; Coenen, M; Liefaard, L; Leavens, K; Nevin, K; Tang, S; Hughes, S; Srinivasan, N; Edwards, K; Anselm, R; Schmidt, T; Stone, J; Savage, C; Wisniacki, N Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S336 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification. (27th September 2022) Authors: Parodis, I; Liefaard, L; Green, Y; Gilbride, JA; Henning, C; Levy, RA; Dimelow, R Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗